Jasper Therapeutics, Inc. (JSPR) has disclosed a new risk, in the Innovation / R&D category.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jasper Therapeutics, Inc. faces significant business risks due to potential delays in the commencement or completion of clinical trials, which could escalate drug development costs and hinder strategic collaborations. These delays may arise from various factors, such as regulatory approval challenges, supply chain disruptions, and recruitment difficulties, which could ultimately impact the company’s ability to generate product revenues. Recent issues in the BEACON study, including atypical results and halted enrollment in the ETESIAN study, underscore the potential for increased costs and slowed development timelines. Such setbacks could allow competitors to gain market advantage and shorten Jasper’s patent protection period, thereby adversely affecting its business and financial prospects.
Overall, Wall Street has a Moderate Buy consensus rating on JSPR stock based on 7 Buys and 4 Holds.
To learn more about Jasper Therapeutics, Inc.’s risk factors, click here.